Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar and Vaginal Atrophy
Conditions
Vulvar and Vaginal Atrophy
Trial Timeline
Jan 1, 2016 → Sep 21, 2016
NCT ID
NCT02668796About Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Vulvar and Vaginal Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02668796. Target conditions include Vulvar and Vaginal Atrophy.
What happened to similar drugs?
0 of 1 similar drugs in Vulvar and Vaginal Atrophy were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02668796 | Phase 3 | Completed |
Competing Products
7 competing products in Vulvar and Vaginal Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 35 |
| Estradiol | Sun Pharmaceutical | Phase 3 | 32 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 39 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 42 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 42 |
| AVA6103 | Avacta Group | Phase 1 | 26 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 25 |